Turn Bio “opens a new paradigm of dermatologic care” with breakthrough skin healing system
07 Dec 2022 --- Cell rejuvenation company Turn Bio is presenting its pre-clinical data suggesting that its proprietary mRNA platform technology, Epigenetic Reprogramming of Aging (ERA) treatment for skin rejuvenation, may be more effective than combination therapies presently used.
“The data suggest we may be close to redefining the care dermatologists can provide their patients,” says Jill Waibel, a board-certified dermatologist and regenerative medicine researcher who presented findings at the Global Aesthetics Conference.
“The potential to improve the quality of patients’ skin – its elasticity and its ability to heal – could change the future of regenerative medicine.”
Biomarker analysis demonstrates ERA’s regenerative impact on fibroblast proliferation and collagen VII production - both of which play an essential role in wound healing and cell migration.
Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company’s ERA technology restores optimal gene expression by combating the effects of aging in the epigenome.
This restores cells’ ability to prevent or treat disease and heal or regenerate tissue. It is touted to help fight incurable chronic diseases.
Skin repair technology
Turn Bio is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology and developing treatments for ophthalmology, osteoarthritis and the muscular system.
Collagen VII expression (in red) is seen at the dermal-epidermal junction after treatment with Turn Bio ERA.The company’s eTurna lipid-based delivery platform uses formulations to precisely deliver benefits to specific organs, tissues and cell types.
“This early research suggests that ERA could significantly improve the balance between key biomarkers of cell aging and cell youthfulness,” shares Hema Sundaram, a board-certified dermatologist and regenerative medicine and cell science researcher, at Turn Bio.
“From an evidence-based perspective, this carries more weight as a rejuvenation strategy than efforts to improve a single biomarker. Research of this type may open the door to a new paradigm of dermatologic care.”
Involving industry experts
Pre-clinical data were presented to dermatologists and industry key opinion leaders attending four global conferences in the past five weeks.
“We believe this promises to be a game-changer for dermatologists, plastic surgeons and their patients,” said Turn Bio CEO Anja Krammer.
“The breakthrough of combining our mRNA-based ERA therapy with our eTurna lipid delivery system, for the first time, shows a reversal from the effects of aging and offers an ability to improve the overall quality of the skin.”
Turn Bio executives have committed to releasing additional data in a January webinar. Details will be announced in the coming weeks.
Edited by Radhika Sikaria
